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Abstract
Efficacy of antitumor vaccination depends to a large extent on antigen targeting to dendritic cells (DCs). Here, we
assessed antitumor immunity induced by attenuated coronavirus vectors which exclusively target DCs in vivo and
express either lymphocyte- or DC-activating cytokines in combination with a GFP-tagged model antigen. Tracking of
in vivo transduced DCs revealed that vectors encoding for Fms-like tyrosine kinase 3 ligand (Flt3L) exhibited a higher
capacity to induce DC maturation compared to vectors delivering IL-2 or IL-15. Moreover, Flt3L vectors more
efficiently induced tumor-specific CD8+ T cells, expanded the epitope repertoire, and provided both prophylactic and
therapeutic tumor immunity. In contrast, IL-2- or IL-15-encoding vectors showed a substantially lower efficacy in
CD8+ T cell priming and failed to protect the host once tumors had been established. Thus, specific in vivo targeting
of DCs with coronavirus vectors in conjunction with appropriate conditioning of the microenvironment through Flt3L
represents an efficient strategy for the generation of therapeutic antitumor immunity.
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Introduction
Immunotherapy of cancer has moved from preclinical
development into clinical practice [1,2]. For example,
prophylactic vaccination using ‘non-self’ antigens such as virus-
derived proteins from human papilloma viruses reduce the
incidence of virus-induced tumors [3,4]. Moreover, the
description of tumor-associated ‘self’ antigens [5,6] has opened
new avenues for vaccination approaches that target eradication
of established tumors cells. Indeed, recent phase III trials have
shown that patient-specific cellular vaccines containing tumor
antigens can improve survival of patients even with advanced
disease [7,8]. However, since the production of tailored
vaccines for individual patients requires laborious and
expensive routines, generation of simple and efficient off-the-
shelf reagents should be fostered.
Biological factors that make the development of therapeutic
antitumor vaccines cumbersome include the
immunosuppressive microenvironment within the tumor tissue
itself [9,10] and remote inhibitory effects such as the
preferential differentiation of T regulatory (Treg) cells [11,12]. It
has been proposed that a combination of tumor antigens with
immune-modulatory cytokines can overcome tumor-induced
immunosuppression and/or –deviation [13]. Cytokines that
foster activation of lymphocytes such as IL-2 or IL-15 have
been evaluated in preclinical models and are currently tested in
clinical studies [14–16] to augment tumor-specific immunity.
Likewise, cytokines that act mainly on myeloid cells such as
granulocyte macrophage colony-stimulating factor (GM-CSF)
or Fms-like tyrosine kinase 3 ligand (Flt3L) have been shown to
improve the efficacy of cancer vaccines [17,18]. However,
cytokines generally exhibit a wide range of functions. For
example, IL-2 is a potent stimulus for the activation of naïve T
cells, but fosters at the same time activation-induced cell death
of CD8+ effector T cells [19] and induces Treg cells in tumor
patients [20]. Likewise, GM-CSF can foster generation and
survival of myeloid suppressor cells [21,22]. Hence, it is
important that cancer vaccines deliver such pleiotropic
cytokines to those cells that optimally induce and maintain
anticancer immune responses.
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Dendritic cells (DCs) sample antigen in peripheral organs,
and transport the immunogenic material to secondary lymphoid
organs to initiate and maintain T and B cell responses [23].
DCs have to be appropriately stimulated to achieve full
differentiation of T cells [24] and to overcome potential
tolerizing stimuli within the microenvironment of secondary
lymphoid organs [25]. Notably, it is important the DCs are
directly activated through pattern-recognition receptors to
achieve full maturation [26] and to successfully induce rejection
of tumors [27].
Attenuated viral vectors exhibit several important advantages
that make them attractive vaccine vehicles for antitumor
vaccination. First, viral vaccines can be produced in large
quantities and stored as off-the-shelf reagents. Second, viruses
generally infect professional antigen presenting cells such as
DCs, and third, viral infection triggers DC maturation [28]. We
have recently suggested to utilize attenuated coronaviruses as
vaccine vectors because (i) these positive-stranded RNA
viruses replicate exclusively in the cytoplasm without a DNA
intermediary, (ii) recent technological advances permit heavy
attenuation without loss of immunogenicity, (iii) their large RNA
genome offer a large cloning capacity, and (iv) both human and
murine coronaviruses efficiently target DCs [29]. In a previous
study, we found that murine coronavirus-based vectors can
deliver multiple antigens and cytokines almost exclusively to
CD11c+ DCs within secondary lymphoid organs [18]. Moreover,
induction of CD8+ T cells directed against human tumor
antigens and efficient transduction of human DCs with tumor
antigen-recombinant human coronavirus 229E [18] indicate
that coronavirus-mediated gene transfer to DCs should be
considered as a versatile approach for antitumor vaccination.
In the present study, we evaluated the impact of Flt3L or
lymphoid cytokines co-expressed with a GFP-tagged model
antigen in murine coronavirus vectors on antitumor immunity.
We found that DCs transduced in vivo with vectors encoding
for Flt3L efficiently activated tumor-specific CD8+ T cells,
broadened the epitope repertoire, and secured therapeutic
tumor immunity. Interestingly, IL-2 and IL-15 showed a
significantly lower adjuvant effect on CD8+ T cell priming and
failed to protect against established tumors indicating that
coronavirus-mediated in vivo targeting of DCs in conjunction
with the myeloid cell-stimulating cytokine Flt3L is well-suited to
generate therapeutic antitumor immunity.
Results
Design of cytokine-expressing coronavirus vectors
Coronavirus-based multigene vaccine vectors were designed
on the basis of the mouse hepatitis virus (MHV) genome
(Figure 1A). To achieve propagation deficiency and to maintain
at the same time replication competence, MHV-encoded
accessory genes (NS2, HE, gene4, gene5a) were deleted and
the non-structural protein 1 (nsp1) was truncated by introducing
a mutation that reduces MHV pathogenicity, but retains
immunogenicity [30]. Moreover, the structural gene E was
deleted to further hinder virion formation [31]. As surrogate
tumor antigen, we used a fusion protein of the enhanced green
fluorescent protein (EGFP) and the gp33 CD8+ T cell epitope
derived from the lymphocytic choriomeningitis virus (LCMV)
glycoprotein. To compare the adjuvant effects of cytokines
acting mainly on myeloid cells versus lymphocytes, the genes
encoding for murine Flt3L, IL-2 or IL-15 were inserted between
the replicase and spike genes (Figure 1A). Propagation of
MHV-based vectors was achieved in 17Cl1 packaging cells
that provide the E protein in trans (Figure 1B). Importantly, the
vectors failed to propagate in primary macrophages (Figure
1C) and DCs (not shown) in vitro, but efficiently delivered their
antigen to DCs resulting in transduction rates of 20 - 40%
(Figure 1D). In vitro transduced peritoneal macrophages and
DCs rapidly produced Flt3L or IL-2 following transduction with
the respective vector (Figure 1E), whereas IL-15 could not be
detected following transduction with MHV-IL15/gp (not shown).
Notably, IL-15 is known as a cytokine that is trans-presented by
IL-15Rα [32] and hence can usually not be measured using
conventional detection systems. Furthermore, we found that
neither transduction with MHV-gp vector induced any of the
three cytokines nor did the cytokine-expressing vectors elicit
non-specific cytokine production (not shown). Thus,
coronavirus vectors can specifically deliver antigen and
different immune-modulatory cytokines to their major target
cells.
Coronavirus vector-induced dendritic cell maturation
We have shown previously that the murine coronavirus
preferentially infects macrophages and DCs in vivo [33].
Moreover, severe attenuation of MHV further focusses its
target cell range to CD11c+ DCs [18]. This pronounced DC-
specificity was not altered by insertion of Flt3L or lymphoid
cytokines. Following i.v. application of 106 vector particles into
C57BL/6 (B6) mice, EGFP expression was detectable mainly in
MHCII (IAb)highCD11c+ DCs (Figure 2A) whereby the cytokines
roughly doubled in vivo transduction efficacy (Figure 2B). In
vivo delivery of IL-2 (Figure 2C) and Flt3L (Figure 2D) resulted
in high cytokine production after 48 h, whereas IL-15 could
neither be detected in serum nor in spleen (not shown).
Importantly, comparable to the transient elevation of GM-CSF
levels following coronavirus-mediated delivery [18], both IL-2
and Flt3L levels had normalized at day 4 post application (not
shown). Since maturation of DCs is critical for induction of
protective immunity [23], we determined expression of the
maturation markers CD40 and CD86 on in vivo transduced,
EGFP+ DCs. As shown in Figure 2E, only the Flt3L-encoding
vectors led to upregulation of both maturation markers.
Interestingly, enhanced expression of CD40 and CD86 was
restricted to those DCs that expressed EGFP (Figure 2F)
indicating that the presence of the viral vector within DCs and
direct production of the myeloid cell-stimulating cytokine Flt3L
led to optimal DC maturation.
Coronavirus vector-delivered cytokines enhance CD8+
T cell induction
To compare the adjuvant effects of the different cytokines
encoded by the coronavirus vectors, we first assessed
magnitude and duration of transgene-specific CD8+ T cell
activation. In addition, to determine cytokine-mediated changes
in epitope usage, we monitored CD8+ T cell responses against
DC Targeting by Coronavirus Vectors
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the H2-Db-binding gp33-41 [34] and the H2-Kb-binding gp34-41
[35] epitopes which are both present in the gp33-EGFP
transgene. Using i.v. application of 105 pfu of each vector, we
found that induction of gp34-specific CD8+ T cells responses
was best supported by Flt3L leading to superior expansion of
tetramer-binding CD8+ T cells and differentiation towards IFN-
γ-producing effector T cells (Figure 3A). Importantly, initial
expansion of gp34-specific CD8+ T cells following vaccination
with MHV-GP/Flt3 was comparable to the responses induced
by the fully replication-competent LCMV (Figure 3B and 3C).
Surprisingly, although IL-2 and IL-15 have been described as
cytokines that support generation of memory T cells [36], the
Flt3L-encoding vector better supported the persistence of
transgene-specific CD8+ T cells (Figure 3B and 3C). As shown
previously [18], MHV-gp vectors failed to raise a substantial
response against the H2-Db-binding gp33 epitope (Figure 3D).
Likewise, the vectors encoding for IL-2 or IL-15 did not elicit a
pronounced CD8+ T cell response against the gp33 epitope,
whereas vector-encoded Flt3L promoted a broadening of the
antigen reactivity towards gp33 (Figure 3D). This finding was
corroborated using adoptive transfer of gp33-specific P14 TCR
transgenic T cells one day before application of the vectors.
Again, Flt3L very efficiently supported the expansion of gp33-
specific CD8+ T cells (Figure 3E) indicating that this cytokine
functions as an optimal adjuvant for DC-specific targeting
approaches.
Tumor immunity elicited by coronavirus vectors
Induction of potent CD8+ T cell responses against tumor
antigens is critical to establish and maintain tumor immunity
[37]. To assess the impact of lymphoid versus Flt3L-mediated
adjuvant effects on protective tumor immunity, we utilized two
Figure 1.  Generation and in vitro characterization of cytokine-encoding murine coronavirus vectors.  (A) Schematic
representation of MHV A59 genome and construction of cytokine-encoding vectors. (B, C) Growth kinetics of the indicated MHV
vectors in 17ECl20 packaging cells (B) and macrophages (Mph) (C). Cells were infected at an MOI of 1 and titres in supernatants
were determined at the indicated time points. (D) Transduction in bone marrow-derived DCs with murine coronavirus vectors. DCs
from B6 mice were transduced with the indicated vectors at a multiplicity of infection (MOI) of 1. Cells were harvested 24 h later and
EGFP expression on CD11c+ cells was assessed. Pooled data from three independent experiments with values indicating mean
percentage ±SEM of EGFP+CD11c+ cells. (E) Cytokine production induced by Flt3L and IL-2 encoding vectors. DCs or
macrophages were transduced at a MOI of 1 and concentration of cytokines in the supernatants was determined by ELISA.
Representative data from one out of three independent experiments.
doi: 10.1371/journal.pone.0081442.g001
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different tumor models which provide compatibility with the
LCMV-GP system due to the expression of a gp33 minigene
[38,39]. In the first model, we assessed metastatic growth of
murine B16F10 melanoma cells. To this end, 5×105 B16F10-
GP or parental B16F10 cells were applied to B6 mice which
resulted in metastatic growth of tumor cells in lungs (Figure
4A). Vaccination of recipient mice on day 7 before tumor
challenge with 105 pfu of the different coronavirus vectors had
completely blocked growth of B16F10-GP tumor cells, whereas
formation of metastatic foci in lungs by parental B16F10 cells
was not affected (Figure 4A). Moreover, prophylactic
vaccination with 102 pfu of IL-2 or IL-15 encoding vectors
reduced the tumor burden, whereas the same dose of Flt3L
vector completely prevented tumor growth (Figure 4A). Careful
titration of the cytokine-encoding vector doses and compilation
of several series of experiments in the prophylactic vaccination
setting revealed that indeed only 102 viral particles of MHV-gp/
Flt3L were sufficient to completely protect the mice from tumor
challenge (Figure 4B). To assess whether cytokine-encoding
vectors can elicit therapeutic tumor immunity, mice were first
inoculated with B16F10-GP tumors and vaccinated 10 days
later with 105 pfu of the different coronavirus vectors. Again ten
days later, i.e. at day 20 post tumor inoculation, melanoma
cells had almost completely covered the whole lung surface in
control and MHV-gp vaccinated mice, whereas therapeutic
vaccination with cytokine-encoding vectors had reduced the
tumor load (Figure 4C). Importantly, determination of affected
lung surface revealed that only vaccination with the Flt3L-
encoding vector was able to significantly reduce the tumor load
(Figure 4D).
Clearance of rapidly growing metastatic tumors is certainly a
challenge for the immune system. However, metastatic tumors
such as the B16 melanoma cells can reach secondary
lymphoid organs and thereby contribute – most likely due to
their MHC class I expression – to the amplification of antitumor
CD8+ T cells [40]. In contrast, tumors which arise in peripheral
Figure 2.  In vivo maturation of DCs following vaccination with coronavirus vectors.  B6 mice were i.v. immunized with 106 pfu
of the indicated viral vectors or left untreated (mock). (A, B) Transduction of DCs as assessed by EGFP expression. Spleens were
collected after 24 h, digested with collagenase and low-density cells were analyzed by flow cytometry. Values in dot plots (A) and
bar graph (B) show the mean percentage ± SEM of EGFP+IAbhigh cells gated on CD11c+ cells. Data from two independent
experiments with three mice per group (n=6). (C, D) Cytokine concentration in serum and spleen homogenates at 24 h post
immunization with Flt3L (C) and IL-2 (D) vectors. Pooled data from three independent experiments with three mice per group (mean
±SEM, n=9). (E) Representative histograms showing expression of the DC maturation markers CD40 and CD86 on EGFP+CD11c+
cells transduced with the indicated vectors. (F) Mean fluorescence values ±SEM (n=9) of CD40 and CD86 expression in transduced
EGFP+CD11c+ cells (+) and non-transduced EGFP+CD11c- cells (-) cells (*, p< 0.05; **, p< 0.01).
doi: 10.1371/journal.pone.0081442.g002
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Figure 3.  Evaluation of CD8+ T cell response induced by cytokine-encoding coronavirus vectors.  (A) Induction of gp34-
specific CD8+ T cells. B6 mice were immunized i.v. with 105 pfu of the indicated vectors. At day 7 post immunization, splenocytes
were analyzed for expression of CD8 and reactivity with H2-Kb/gp34-tetramers, and were tested for gp34-specific IFN-γ production.
Values indicate mean percentages of tet+ cells ± SEM (upper row) or mean percentages of IFN-γ+ cells ± SEM (lower row) in the
CD8+ T-cell compartment (pooled data of 3 independent experiments, n=12 mice). (B and C) Duration of vector-induced CD8+ T cell
responses. B6 mice were immunized i.v. with 105 pfu of the indicated vectors or infected with 200 pfu of LCMV WE. Frequencies (B)
and total numbers (C) of splenic CD8+ tet-gp34-binding T cells were determined at the indicated time points (mean percentages or
total numbers of tet-gp34+ cells ±SEM, n=6-12 mice per time point); nd, not detectable. (D) Induction of gp33-specific CD8+ T cells
as determined by tetramer analysis on day 7 post i.v. immunization with the indicated vectors (mean percentages of tet-gp33+ cells
± SEM, n=8 mice). (E) Expansion of gp33-specific P14 TCR transgenic CD8+ T cells. One day before immunization with 105 pfu of
the indicated vectors, CD45.2+ B6 mice had received 105 CD45.1+ P14 splenocytes. Expansion of CD45.1+CD8+ T cells in spleens
was assessed on day 7 post immunization (mean percentages of CD45.1+CD8+ T cells ±SEM, n=8 mice) (*, p< 0.05; **, p< 0.01; ***,
p< 0.001; comparison with gp control vector).
doi: 10.1371/journal.pone.0081442.g003
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tissues can escape immune surveillance in the absence of
appropriately activated T cells [41]. To assess whether
coronavirus vector-based vaccination can prevent growth of
such peripherally growing tumors, we applied 5×105 LCMV-GP
recombinant Lewis lung carcinoma (LLC) cells s.c. into
prophylactically vaccinated B6 mice. As shown in Figure 5A, all
coronavirus-based vectors were able to protect the animals
under these conditions. However, when we assessed the
efficacy of the vaccines in a therapeutic approach, i.e. applying
the vaccines on day 4 post tumor inoculation, only FLt3L-
encoding vectors achieved an almost complete block of tumor
growth (Figure 5B). Taken together, these results indicate that
Figure 4.  Coronavirus vector-induced immunity against a metastasizing tumor.  (A, B) B6 mice were i.v. immunized with the
indicated doses of the different vectors or infected with 200 pfu LCMV WE. PBS was administered as negative control. Seven days
later mice were challenged with 5×105 B16F10-gp melanoma cells or the parental B16F10 cells. (A) Representative
microphotographs of lungs on day 12 post tumor inoculation. (B) Number of metastatic foci per lung was determined 12 days after
challenge (pooled data from three independent experiments, mean ±SEM, n=6-9 mice per time point). (C, D) Assessment of
therapeutic tumor immunity. B6 mice received 5×105 B16F10-gp melanoma cells i.v. at day 0 and were vaccinated 10 days later
with 105 pfu of the indicated vectors or left untreated. (C) Representative microphotographs of affected lungs on day 20 after tumor
inoculation. (D) Disease severity was quantified by black pixel counting on lung surfaces on day 20. Values represent mean
percentage ±SEM (n=6-8 mice) of affected lung surface. Statistical analysis in (D) was performed using one way ANOVA with
Tukey’s post analysis (**, p< 0.01; ns, non-significant).
doi: 10.1371/journal.pone.0081442.g004
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different cytokines can improve immunogenicity of coronavirus
vectors. However, maturation of DCs through vector-encoded
cytokines that preferentially activate myeloid cells is essential
for the generation of therapeutic tumor immunity.
Discussion
Recent clinical trials have shown that viral vector-based
vaccination against cancer is feasible, safe and suitable to
achieve protective tumor immunity [42]. For example, a
Figure 5.  Prophylactic and therapeutic tumor immunity
against a peripheral solid tumor.  (A) B6 mice were i.v.
immunized with 105 pfu of the different vectors or received PBS
as control. Seven days later, 5×105 gp-recombinant Lewis lung
carcinoma cells were injected s.c. on the left flank. (B)
Assessment of therapeutic tumor immunity induced by 105 pfu
of the different vectors applied on day 4 post s.c. inoculation
with 5×105 gp-recombinant Lewis lung carcinoma cells. Tumor
growth was monitored on the indicated days. Values indicate
mean tumor volume ±SEM (n=9 mice). Values in parentheses
indicate number of growing tumors of inoculated tumors.
Statistical analysis in (B) was performed using one way
ANOVA with Bonferroni multiple comparison test (**, p< 0.01;
***, p< 0.001; ns, non-significant).
doi: 10.1371/journal.pone.0081442.g005
randomized, placebo-controlled study in patients suffering from
castration-resistant prostate carcinoma (n=125) showed that a
heterologous prime-boost regimen with different poxvirus
vectors delivering prostate-specific antigen increased the
median survival by 8.5 months [43]. Notably, this approach
using an off-the-shelf vaccine yielded an efficacy comparable
to the personalized cellular vaccine Sipuleucel which increases
survival of patients suffering from incurable prostate cancer by
4.1 months [7]. Nonetheless, the high immunogenicity of viral
vectors results in the induction of antiviral immunity which
makes heterologous prime-boost schemes necessary to
guarantee repeated exposure to the target antigen [44]. Hence,
coronavirus vectors based on human DC-targeting common
cold viruses [18], represent a potential asset for future clinical
trials that utilize heterologous prime-boost approaches.
Importantly, vaccination with attenuated murine coronavirus
vectors permits usage of the vectors even in homologous
prime-boost schemes hence leading to the maintenance of
effector T cells at high frequencies [18]. Since human
coronaviruses causing common cold frequently re-infect their
hosts [45], it is possible that this human viral vector family may
be utilized as well in homologous prime-boost approaches.
The ability of DCs to induce antigen-specific tumor immunity
can be enhanced by immunological adjuvants such as toll-like
receptor (TLR) ligands which lead to optimal immune activation
only when DCs are stimulated directly through their TLRs
[26,27]. Likewise, cytokines that stimulate the myeloid
compartment such as the granulocyte-macrophage colony-
stimulating factor (GM-CSF), facilitate DC maturation and
foster their survival [46]. Our previous study revealed the
importance of DC-specific GM-CSF delivery for both DC
maturation and prolongation of antigen presentation through
improved DC survival leading to sustained CD8+ T cells
immunity against viral infection and tumors [18]. Here, we
found that a second myeloid cell-stimulating cytokine very
efficiently enhanced the immunogenicity of coronavirus vectors.
Notably, the Flt3L vectors were even more effective than the
GM-CSF vectors in preventing metastatic growth of melanoma
cells [18]. Moreover, MHV-Flt3L/gp vectors, but not GM-CSF-
encoding vectors [18], elicited a broadening of the epitope
repertoire with presentation of two epitopes from the gp33
minigene. Thus, the iterative approach of coronavirus vector
optimization using a single model antigen and standardized
read-out methods facilitates the definition of cytokines that
display optimal adjuvant effects for this vaccine.
In this study, we also evaluated the adjuvant effect of
cytokines that act more downstream in the immune activation
cascade. The lymphocyte-stimulating cytokines IL-2 and IL-15
are known to enhance proliferation of T cells, to foster
differentiation of CD8+ T cells and to control formation of T cell
memory [36]. However, despite sharing two out of three of their
receptor units (common gamma chain and IL-2/IL-15β-R) these
cytokines impact differently on T cell differentiation. IL-2 is most
important for the early expansion of T cells and via activation-
induced cell death, the limitation of the T cell overshoot [47].
IL-15, on the other hand, is essential for survival of high-affinity
T cells during the memory phase [48] and ensures thereby the
maintenance of protective T cell memory responses. It is
DC Targeting by Coronavirus Vectors
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important to note that both IL-2 and IL-15 are highly efficient
adjuvants that have been shown to enhance tumor-specific T
cell responses [36]. Our data confirm that IL-2 and IL-15
improve CD8+ T cell activation and induction of prophylactic
tumor immunity, also when incorporated in a coronavirus-
based vaccine that delivers the cytokines directly to DCs in
vivo.
It is interesting to note that neither the secreted and
systemically acting IL-2 nor the more locally acting, trans-
presented IL-15 reached the efficacy of the DC-stimulating
Flt3L. Flt3L is a highly immunostimulatory cytokine that
supports, for example, control of parasitic infections both in
mice and humans [49]. Moreover, Flt3L efficiently mobilizes DC
precursors, for example in humans with metastatic colon
cancer [50]. The results of the present study suggest that high
vaccine immunogenicity can be achieved through direct
transduction of DCs via a coronavirus vector with concomitant
delivery of a potent DC maturation factor such as Flt3L.
Clearly, further analyses are warranted to reveal the molecular
events involved in Flt3L-mediated adjuvant effects in this
system. In addition, it is possible that a combination of different
cytokines delivered by coronavirus vectors in homologous
prime-boost regimen, e.g. Flt3L followed by IL-15 vectors or
vice versa, will result in a further improvement of coronavirus
vector-induced antitumor immunity.
In conclusion, incorporation of cytokines into coronavirus
vectors substantially improves their performance. Since these
vectors almost exclusively target DCs, expression of cytokines
that facilitate DC maturation and foster their survival such as
GM-CSF or Flt3L, is highly efficient and facilitates generation
and maintenance of antitumor CD8+ T cells. Therefore,
coronavirus-based vectors that express DC-stimulating




Experiments were performed in accordance with federal and
cantonal guidelines under permission numbers SG09/92,
SG11/06, and SG11/10 following review and approval by the
Cantonal Veterinary Office (St. Gallen, Switzerland).
Mice, cells and viruses
C57BL/6 mice were obtained from Charles River
Laboratories (Sulzfeld Germany). P14 TCR transgenic mice
were obtained from the Swiss Immunological Mutant Mouse
Repository (Zurich, Switzerland). All mice were maintained in
individual and ventilated cages and were used between 6 and
9 weeks of age. 17Cl1 cells were a kind gift from S. G. Sawicki
(Medical University of Ohio, Toledo, OH). The LCMV WE strain
was obtained from R. M. Zinkernagel (Universität Zürich,
Switzerland). Titration of MHV vectors has been performed as
described previously [33].
Cloning and generation of recombinant MHV-based
vectors
Generation of recombinant MHV vectors is based on reverse
genetic systems established for MHV-A59 [51]. Molecular
cloning and production of recombinant coronavirus particles
was performed as previously described [18].
Isolation of dendritic cells and macrophages, flow
cytometry
Bone marrow–derived DCs were generated by culturing
erythrocyte-depleted bone marrow cells for 6 to 7 days in the
presence of GM-CSF containing supernatant from the cell line
X63-GM-CSF (kindly provided by Antonius Rolink, University of
Basel, Basel, Switzerland) as described previously [33]. DCs
were further purified using Optiprep density gradient
centrifugation. Splenocytes were obtained from spleens of B6
mice following digestion with collagenase type II for 20 min at
37°C and resuspended in RPMI/5% FCS. For isolation of the
low density cells, splenocytes were resuspended in PBS
supplemented with 2% FCS, 2 mM EDTA and overlaid on 20%
Optiprep density gradient medium (Sigma-Aldrich Co. Basel,
Switzerland). After centrifugation at 700×g for 15 min, low
density cells were recovered from the interface and
resuspended in RPMI/5% FCS. Cells were stained with
different lineage markers and analyzed for EGFP expression
with a FACSCanto flow cytometer using the FACS Diva
software (BD Biosciences). Antibodies used in this study were
purchased from BD Biosciences Pharmingen (CD11c-PE), or
Biolegend (CD40-APC, CD86-APC, IAb-Alexa fluor 647 ).
Tetramer analysis and intracellular cytokine staining
Enumeration of virus- specific CD8+ T cells and ex vivo
production of IFN-γ were determined by tetramer staining and
intracellular cytokine staining, respectively, as described
previously [30]. Organs were removed at the indicated time
points following immunization with MHV-based vectors.
Tetramers were synthesized and applied for staining of blood
and spleen samples as previously described [52]. For
intracellular cytokine staining, single cell suspensions of 106
splenocytes were incubated for 5 h at 37°C in 96-well round-
bottom plates in 200 μl culture medium containing Brefeldin A
(Sigma). Cells were stimulated with phorbolmyristateacetate
(PMA, 50 ng/ml) and ionomycin (500 ng/ml) (both purchased
from Sigma, Buchs, Switzerland) as positive control or left
untreated as a negative control. For analysis of peptide-specific
responses, cells were stimulated with 10-6 M of the indicated
peptides. Cells were further surface-stained with CD8-APC
(eBiosciences), permeabilized with Cytofix-Cytoperm (BD
Biosciences) and intracellularly-stained with IFN-γ-PE. The
percentage of tet+CD8+ T cells and CD8+ T cells producing IFN-
γ was determined using a FACSCanto flow cytometer using the
FACS Diva software (BD Biosciences). GP33 (KAVYNFATC)
and GP34 (AVYNFATC) peptides were purchased from
Neosystem (Strasbourg, France).
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Tumor models
B16F10-GP melanoma cells expressing the LCMV gp33
epitope [38] and parental B16F10 cells were kindly provided by
Dr. H. Pircher (University of Freiburg, Germany). The B16F10-
GP melanoma cells were cultivated under G418 (200 µg/ml)
(Life Technologies, Gaithersburg, MD) selection. For
prophylactic vaccination experiments, mice were immunized
with MHV-based vectors seven days before i.v. tumor
challenge with 5×105 tumor cells. Protection was determined as
numbers of metastasic foci per lung on day twelve post tumor
inoculation. For therapeutic vaccination, mice received 5×105
tumor cells i.v. and were immunized ten days later with the
indicated vectors. Tumor clearance was determined on day
twenty and recorded as percentage of affected lung surface.
LLC cells expressing H-2Db-restricted peptide 33-41 of the
LCMV glycoprotein [39] were kindly provided by Dr. Franca
Ronchese (University of Wellington, New Zealand). Efficacy of
prophylactic vaccination was assessed by immunizing B6 mice
i.v. with 105 pfu coronavirus vectors seven days before s.c.
challenge with 5×105 tumor cells in the left flank. Therapeutic
vaccination was done using i.v. application of 105 pfu
coronavirus vectors in B6 mice which had received 5×105
tumor s.c. in the left flank four days previously. At the indicated
time points, tumor volume was recorded as V=π x abc/6,
whereby a, b and c are the orthogonal diameters.
Statistical Analysis
Statistical analyses were performed with Graphpad Prism 5.0
using non-paired, two tailed Student’s t test. Comparison
between different groups was done using one way ANOVA with
Tukey’s post test or with Bonferroni multiple comparison test as
indicated. Statistical significance was defined as p < 0.05.
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